Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) has provided an announcement.
Beijing Tong Ren Tang Chinese Medicine Company Limited has called an extraordinary general meeting in Hong Kong on 11 February 2026 for shareholders to vote on approving a renewed PRC distribution framework agreement with its parent-related entity, China Beijing Tong Ren Tang Group Co., Ltd., including proposed annual transaction caps through 2028. The meeting will also authorize a company director to execute all necessary documents and actions to implement the renewed agreement, a step that could shape the group’s distribution structure and governance of related-party transactions over the next three financial years.
The most recent analyst rating on (HK:3613) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Company Limited is a Hong Kong-incorporated company engaged in the Chinese medicine sector, focusing on the production and distribution of traditional Chinese medicinal products. The company leverages its association with the longstanding Tong Ren Tang brand to serve domestic and international markets for herbal and traditional remedies.
Average Trading Volume: 1,016,119
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.28B
Find detailed analytics on 3613 stock on TipRanks’ Stock Analysis page.